Arvee Laboratories (India) Ltd. (IN:ARVEE)
:ARVEE
Want to see IN:ARVEE full AI Analyst Report?
ARVEE Stock Chart & Stats
₹242.32
-₹0.03(-0.02%)
At close: 4:00 PM EST
₹242.32
-₹0.03(-0.02%)
Day’s Range― - ―
52-Week Range₹129.11 - ₹290.78
Previous CloseN/A
Volume716.00
Average Volume (3M)1.40K
Market Cap
₹1.85B
Enterprise Value₹1.88B
Total Cash (Recent Filing)₹59.75M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)32.2
Beta1.18
Next Earnings
May 22, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.66
Shares Outstanding11,020,000
10 Day Avg. Volume2,098
30 Day Avg. Volume1,398
Financial Highlights & Ratios
PEG Ratio0.72
Price to Book (P/B)5.18
Price to Sales (P/S)4.20
P/FCF Ratio-93.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet / Low LeverageA low debt-to-equity profile and strong equity ratio provide durable financial flexibility. This conservatism reduces refinancing and solvency risk, enabling the company to fund capex, absorb demand shocks, and pursue opportunistic investments without pressuring cash flow.
Positive ROE And Stable MarginsConsistent positive ROE and generally stable gross and net margins indicate sustainable operating economics. Stable margins provide a cushion during revenue volatility, support internal reinvestment, and reflect structural cost or pricing advantages in specialty pharma-related products.
Exposure To Pharmaceutical / Healthcare End MarketsOperating in specialty chemicals for pharmaceuticals ties the business to defensive, demand-stable end markets. Long product development cycles and regulatory barriers can create durable revenue streams and higher switching costs versus commoditized chemical segments.
Bears Say
Recent Negative Free Cash FlowNegative free cash flow and weak cash conversion highlight a structural challenge converting profits into deployable cash. This limits capacity to self-fund growth, increases reliance on external financing, and can constrain working capital or R&D investment over the medium term.
Inconsistent And Falling Revenue TrendVolatile historical revenue and a recent decline reduce predictability of future earnings and hamper long-term planning. Persistent top-line instability can strain margins, impede scale economics, and make investment in capacity or product development riskier for management.
Limited Scale And Low Trading LiquidityA small employee base and low average trading volume suggest limited operational scale and market liquidity. This can restrict R&D, geographic expansion, and bargaining power with buyers or suppliers, and may raise the cost or complexity of accessing capital for growth.
Arvee Laboratories (India) Ltd. News
ARVEE FAQ
What was Arvee Laboratories (India) Ltd.’s price range in the past 12 months?
Arvee Laboratories (India) Ltd. lowest stock price was ₹129.11 and its highest was ₹290.78 in the past 12 months.
What is Arvee Laboratories (India) Ltd.’s market cap?
Arvee Laboratories (India) Ltd.’s market cap is ₹1.85B.
When is Arvee Laboratories (India) Ltd.’s upcoming earnings report date?
Arvee Laboratories (India) Ltd.’s upcoming earnings report date is May 22, 2026 which is in 21 days.
How were Arvee Laboratories (India) Ltd.’s earnings last quarter?
Arvee Laboratories (India) Ltd. released its earnings results on Feb 13, 2026. The company reported ₹1.658 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.658.
Is Arvee Laboratories (India) Ltd. overvalued?
According to Wall Street analysts Arvee Laboratories (India) Ltd.’s price is currently Overvalued.
Does Arvee Laboratories (India) Ltd. pay dividends?
Arvee Laboratories (India) Ltd. does not currently pay dividends.
What is Arvee Laboratories (India) Ltd.’s EPS estimate?
Arvee Laboratories (India) Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Arvee Laboratories (India) Ltd. have?
Arvee Laboratories (India) Ltd. has 11,020,000 shares outstanding.
What happened to Arvee Laboratories (India) Ltd.’s price movement after its last earnings report?
Arvee Laboratories (India) Ltd. reported an EPS of ₹1.658 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.977%.
Which hedge fund is a major shareholder of Arvee Laboratories (India) Ltd.?
Currently, no hedge funds are holding shares in IN:ARVEE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Arvee Laboratories (India) Ltd.
Arvee Laboratories (India) Ltd. manufactures and sells various specialized chemicals in India. The company provides polymer modifiers, including dimethyl 5-sodiosulfoisophthalate, 5-sulfoisophthalic acid mono sodium salt, 5-sulfoisophthalic acid mono lithium salt, and 5-sodiosulfo-bis-(ß-hydroxyethyl)-isophthalate; and contrast media intermediates, such as 5-nitroisophthalic acid, dimethyl 5-nitroisophthalate, monomethyl 5-nitroisophthalate, 5-hydroxyisophthalic acid, 5-aminoisophthalic acid, and dimethyl 5-aminoisophthalate, as well as 3,5-dinitrobenzoic acid and 3,5-diamino benzoic acid. It also offers drug intermediates comprising 2-acetyl thiophene, thiophene-2-carboxaldehyde, 4amino pyridine, and 2chloro5nitrobenzoic acid. In addition, the company exports its products. Arvee Laboratories (India) Ltd. was incorporated in 2012 and is based in Ahmedabad, India.
Technical Analysis
Balaxi Pharmaceuticals Limited
―
Biofil Chemicals & Pharmaceuticals Ltd.
―
―
Lasa Supergenerics Ltd.
―
Vivimed Labs Limited
―